Matrix Metalloproteinase-9 (MMP-9) Gene Polymorphism in Stroke Patients

Overview

Journal Neuromolecular Med

Specialty Biochemistry

Date 2015 Sep 3

PMID 26330106

Citations 21

Authors

Kinga Buraczynska

Jacek Kurzepa

Andrzej Ksiazek

Monika Buraczynska

Konrad Rejdak

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMPs), endopeptidases degrading extracellular matrix, play an important role in the pathogenesis of atherosclerosis and vascular disease. The aim of this study was to evaluate the association between the C(-1562)T functional polymorphism in the MMP-9 gene and risk of stroke. We examined 322 patients with stroke and 410 controls. In the patient group, 52 % had type 2 diabetes. All subjects were genotyped for the C(-1562)T polymorphism by polymerase chain reaction and restriction analysis. A significant increase in T allele and CT + TT genotype frequencies was observed in patients compared with controls (OR 1.73, 95 % CI 1.34-2.23 and 1.89, 95 % CI 1.39-2.56, respectively). The T allele carriers were younger at the onset of stroke (63.5 ± 11.7 years) than patients with CC genotype (71 ± 14.1 years) (p = 0.0002). The comparison between patients with T2DM and without it showed that the T allele and CT + TT genotype were more frequent in T2DM patients (OR 1.48, 95 % CI 1.03-2.12 for T allele and 1.44, 95 % CI 1.93-2.24 for CT + TT genotype). In conclusion, our findings suggest that MMP-9 C(-1562)T polymorphism is significantly associated with risk of stroke in patients with and without T2DM.

Citing Articles

Identification of m6A-Related Biomarkers in Systemic Lupus Erythematosus: A Bioinformation-Based Analysis.

Tian Y, Tao K, Li S, Chen X, Wang R, Zhang M J Inflamm Res. 2024; 17:507-526.

PMID: 38298525 PMC: 10829513. DOI: 10.2147/JIR.S439779.

Identification of Molecular Mechanisms Responsible for the MMP-9-1562C/T Dependent Differential Regulation of Matrix Metalloproteinase-9 Expression in Human Neuron-like Cells.

Pabian-Jewula S, Ambrozek-Latecka M, Bragiel-Pieczonka A, Nowicka K, Rylski M Genes (Basel). 2023; 14(11).

PMID: 38002971 PMC: 10671763. DOI: 10.3390/genes14112028.

Gene Polymorphism (rs3918242) Increases the Risk of Cardiovascular Disease in Type 2 Diabetes Patients.

Buraczynska M, Wrzos S, Zaluska W J Clin Med. 2023; 12(22).

PMID: 38002605 PMC: 10672737. DOI: 10.3390/jcm12226990.

Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.

Rashid Z, Bardaweel S Int J Mol Sci. 2023; 24(15).

PMID: 37569509 PMC: 10418771. DOI: 10.3390/ijms241512133.

Does the functional polymorphism-1562C/T of MMP-9 gene influence brain disorders?.

Pabian-Jewula S, Rylski M Front Cell Neurosci. 2023; 17:1110967.

PMID: 37206663 PMC: 10188926. DOI: 10.3389/fncel.2023.1110967.

References

Manso H, Krug T, Sobral J, Albergaria I, Gaspar G, Ferro J . Variants of the Matrix Metalloproteinase-2 but not the Matrix Metalloproteinase-9 genes significantly influence functional outcome after stroke. BMC Med Genet. 2010; 11:40. PMC: 2851591. DOI: 10.1186/1471-2350-11-40. View

Galis Z, Khatri J . Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90(3):251-62. View

Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S . Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999; 105(5):418-23. DOI: 10.1007/s004390051124. View

Banerjee C, Moon Y, Paik M, Rundek T, Mora-McLaughlin C, Vieira J . Duration of diabetes and risk of ischemic stroke: the Northern Manhattan Study. Stroke. 2012; 43(5):1212-7. PMC: 3336044. DOI: 10.1161/STROKEAHA.111.641381. View

Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L . Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013; 2013:928315. PMC: 3694547. DOI: 10.1155/2013/928315. View

Zhang B, Ye S, Herrmann S, Eriksson P, de Maat M, Evans A . Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999; 99(14):1788-94. DOI: 10.1161/01.cir.99.14.1788. View

Katakami N, Takahara M, Kaneto H, Shimizu I, Ohno K, Ishibashi F . Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes. Diabetes Care. 2009; 33(2):390-5. PMC: 2809289. DOI: 10.2337/dc09-1518. View

Purcell S, Cherny S, Sham P . Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2002; 19(1):149-50. DOI: 10.1093/bioinformatics/19.1.149. View

Demir R, Ulvi H, Ozel L, Ozdemir G, Guzelcik M, Aygul R . Relationship between plasma metalloproteinase-9 levels and volume and severity of infarct in patients with acute ischemic stroke. Acta Neurol Belg. 2012; 112(4):351-6. DOI: 10.1007/s13760-012-0067-4. View

10.

Cojocarui I, Cojocaru M, Sapira V, Socoliuc G, Hertea C, Paveliu S . Changes in plasma matrix metalloproteinase-9 levels in patients with acute ischemic stroke. Rom J Intern Med. 2013; 50(2):155-8. View

11.

Candelario-Jalil E, Yang Y, Rosenberg G . Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2008; 158(3):983-94. PMC: 3584171. DOI: 10.1016/j.neuroscience.2008.06.025. View

12.

Visse R, Nagase H . Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8):827-39. DOI: 10.1161/01.RES.0000070112.80711.3D. View

13.

Siefert S, Sarkar R . Matrix metalloproteinases in vascular physiology and disease. Vascular. 2012; 20(4):210-6. DOI: 10.1258/vasc.2011.201202. View

14.

Medley T, Cole T, Dart A, Gatzka C, Kingwell B . Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004; 24(8):1479-84. DOI: 10.1161/01.ATV.0000135656.49158.95. View

15.

Goracy J, Goracy I, Brykczynski M, Peregud-Pogorzelska M, Naruszewicz M, Ciechanowicz A . [The C(-1562)T polymorphism in the promoter of the matrix metalloproteinase-9 (MMP-9) gene and coronary atherosclerosis]. Pol Arch Med Wewn. 2006; 110(5):1275-81. View

16.

Kaplan R, Smith N, Zucker S, Heckbert S, Rice K, Psaty B . Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis. 2008; 201(1):130-7. PMC: 3077423. DOI: 10.1016/j.atherosclerosis.2008.01.003. View

17.

Djelilovic-Vranic J, Alajbegovic A, Zelija-Asimi V, Niksic M, Tiric-Campara M, Salcic S . Predilection role diabetes mellitus and dyslipidemia in the onset of ischemic stroke. Med Arch. 2013; 67(2):120-3. DOI: 10.5455/medarh.2013.67.120-123. View

18.

Szczudlik P, Borratynska A . Association between the -1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population. Neurol Neurochir Pol. 2010; 44(4):350-7. DOI: 10.1016/s0028-3843(14)60294-2. View

19.

Kurzepa J, Kurzepa J, Golab P, Czerska S, Bielewicz J . The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int J Neurosci. 2013; 124(10):707-16. DOI: 10.3109/00207454.2013.872102. View

20.

Fatar M, Stroick M, Griebe M, Hennerici M . Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 2005; 20(3):141-51. DOI: 10.1159/000087197. View